Meet the Neighbors — Food, Drug & Device
These profiles are illustrative composites. The numbers — SNAP FY25 maximum benefit ~$8.05/person/day with 10-30% corner-store unit-price premium; April 2025 FDA RIF affecting ~3,500 personnel = 19% of workforce (per MC-07); September 20, 2025 USDA ERS Household Food Security report series termination with final ERR-358 December 2025 documenting 13.7% household FI (Black 24.4% / Latinx 20.2% / White 10.1%) per MC-08; April 25, 2025 Salmonella Framework withdrawal (90 FR 17344) and December 2025 NRTE breaded stuffed chicken sampling delay per MC-03; cheaper-cut Salmonella detection rates (4.14% chicken carcasses / 7.62% chicken parts / 24.2% comminuted chicken — 2022 FSIS data); IRA Medicare Drug Price Negotiation Program first-round MFPs effective January 1, 2026 with Round 2 effective January 1, 2027 per MC-04; ~20% PA pharmacy reduction post-Rite-Aid with SVI 30-40% closure correlation; CDER ~1,000-employee loss over three months per MC-07; Casgevy globally infused 64 patients in 2025 with ~164 cumulative US uptake through 2025 per MC-05; March 16, 2026 ACIP court ruling (Judge Brian E. Murphy, D. Mass.) per MC-02; April 9, 2026 HHS ACIP charter rewrite; LDT vacatur March 31, 2025; menthol cigarette ban withdrawal January 21, 2025 per MC-06 and April 2025 CTP Office of Regulations RIF per MC-07; SNAP-authorized retailer interior advertising 3.43x pattern in compound-disadvantage sub-areas; DEA Marijuana Schedule III Final Order effective April 28, 2026 per MC-01 with 60-day priority window through ~June 27, 2026; Kensington compound-incidence with medetomidine 83% of Philadelphia drug supply by March 2025 — are derived from current law, verified primary reporting, and the verified file's Phase 3 verification cycle applied to documented PA-3 conditions. The neighborhoods are real and their statistical character is real. The people are constructed to make the structural patterns visible at the scale of a household, patient, or small business. They have no names and are not based on any identifiable individual.
Filter the profiles
Showing 21 of 21 profiles
SNAP-using household of four at 130% FPL in North Philadelphia at the corner-store benefit-vs-need gap
North/Northwest Philadelphia Core
PA-3 constituent household of four at ~130% FPL · residing in Strawberry Mansion, Hunting Park, or Fairhill · within North/Northwest Philadelphia Core compound-disadvantage geography · 36.9% household FI in studied tracts (Drexel-Dornsife) · SNAP FY25 maximum benefit ~$8.05/person/day = $32.20/day household of 4 · corner-store unit-price premium 10-30% above supermarket
$32.20/day nominal benefit × corner-store unit-price premium reduces effective purchasing power to ~$22.50-$29.30/day in supermarket-pricing terms; post-2021 27% food cost inflation compounds. PDPH Get Healthy Philly Food Bucks doubles SNAP value at participating farmers markets; coverage by sub-area pending direct retrieval. OBBBA P.L. 119-21's $186B SNAP cut compounds the benefit-rate calibration question; USDA ERS termination (September 20, 2025; final ERR-358 December 2025) removes the federal data infrastructure characterizing the pattern (G1-SD1-01 + G1-SD1-04; MC-08).
Black PA-3 woman cosmetics consumer in MoCRA implementation-lag window
West Philadelphia Core
PA-3 constituent Black woman cosmetics consumer · documented hair-product chemical-exposure profile (para-phenylenediamine, formaldehyde-releasing preservatives, parabens, phthalates) · across all four PA-3 sub-areas · the pattern MoCRA was designed to address · MoCRA enacted 2022 with final regulations phased through 2026-2028
Current product inventory at retail predates final regulations; consumer encounters product produced under pre-MoCRA regulatory regime through implementation-lag interval. April 2025 FDA RIF reduced HFP/OII capacity at moment of MoCRA implementation. XC-11 application — small / Black-owned cosmetics manufacturers under MoCRA exemption thresholds may, in operational consequence, exclude from the remediation regime the precise subset of manufacturers whose products are most concentrated in the consumer-base most affected by the pattern MoCRA was designed to address (F4-T2P2-SD1-MoCRA-1 verification pending; G1-SD1-03; XC-11 framework).
Small carnicería or ethnic-market retailer in South Philadelphia at the §6-300 / §6-301 jurisdictional interface
South/Southwest Philadelphia
PA-3 constituent small carnicería, Vietnamese market, or ethnic-grocery retailer · Italian Market / 9th Street corridor, Washington Avenue, or 7th Street · small / independent retail establishment · PA Food Safety Act + Title 6 Chapter 6-300 + Title 6 §6-301 (USDA jurisdictional carve-out at retail per SD2) jurisdictional interface
PDPH OFP plan review; construction inspection; operational inspection; license fee; food handler certification; routine inspection at 6-12 month interval. PDPH OFP inspection density variation by sub-area pending direct retrieval (F4-T2P2-SD1-2). The Title 6 §6-300 / §6-301 interface particularly affects small carnicerías where retail-cut meat processing interacts with USDA FSIS jurisdictional carve-out for retail. PDPH Healthy Corner Store Initiative provides structural-actor support at participating retailers; the differential compliance burden for small / independent retailers without that support is the structural pattern this profile encounters (G1-SD1-06; XC-11 framing).
SNAP-using household purchasing cheaper-cut poultry as primary protein in North Philadelphia
North/Northwest Philadelphia Core
PA-3 constituent SNAP-using household at ~130% FPL · Strawberry Mansion, Hunting Park, or Fairhill · within North/Northwest Philadelphia Core compound-disadvantage geography · purchasing cheaper-cut poultry (parts; comminuted) as primary protein · Pathogen Reduction/HACCP Final Rule (1996) operative at slaughter
Salmonella detection rises with processing: 4.14% in chicken carcasses; 7.62% in chicken parts; 24.2% in comminuted chicken (2022 FSIS data). Cheaper-cut concentration (parts vs. whole-bird selection by household economics) intersects Salmonella prevalence at slaughter directly — concentrating in lower-income predominantly Black PA-3 consumer households. The withdrawn Salmonella Framework (April 25, 2025; 90 FR 17344) would have added preventive-controls overlay addressing ~25% of foodborne Salmonella illness; the December 2025 NRTE breaded stuffed chicken sampling delay compounds the gap (G1-SD2-02 + G1-SD2-05; MC-03).
Halal-observant consumer along the West Philadelphia 52nd Street corridor
West Philadelphia Core
PA-3 constituent halal-observant consumer · West Philadelphia 52nd Street corridor · seeking ritually-slaughtered meat at retail corridor · FMIA § 1902 ritual-slaughter exemption operative at slaughter · retail-level certification varies by retailer (third-party ritual-certifying organizations)
Independent halal butcher at 52nd Street corridor functions as retail anchor. Independent halal / kosher retail operates within PA Food Safety Act + Title 6 §6-301 jurisdictional layer; small retail relies on upstream federally-inspected supply chain (whose tool just withdrew) without direct FSIS-jurisdiction recourse at retail. XC-11 application — independent halal butchers carry differential compliance burden + customer-trust + Salmonella-tool-withdrawal effects against corporate-chain retail; the small / independent retail layer that anchors specific PA-3 communities absorbs the additional structural risk (G1-SD2-04 + G1-SD2-07; XC-11 framework).
Small carnicería operator at the Italian Market / 9th Street corridor in South Philadelphia
South/Southwest Philadelphia
PA-3 constituent small carnicería or ethnic-market retailer · Italian Market / 9th Street corridor, Washington Avenue, or 7th Street · operating with USDA-exempt portion under Title 6 §6-301 jurisdictional carve-out · PA Retail Food Facility Safety Act + PADA retail inspection + PDPH OFP retail food licensing
Federal-FSIS jurisdiction ends at retail; state-PADA + local-PDPH-OFP picks up; compliance-burden distribution falls differentially on small operations under multi-jurisdictional compliance regime. XC-11 application — small carnicerías + small ethnic-market retail in South Philadelphia carnicería corridors operate concentrated in this pathway; compliance burden under PA Retail Food Facility Safety Act + Title 6 §6-300 + §6-301 jurisdictional layering operates differentially against corporate-chain butcher / deli operations whose compliance infrastructure absorbs regulatory burden differently (G1-SD2-07; XC-11 framing).
Medicare Part D beneficiary on IRA-MFP-list drug in pharmacy-desert sub-area
South/Southwest Philadelphia
PA-3 constituent Medicare Part D beneficiary · one of the IRA-MFP-list drugs (effective January 1, 2026) · residing in documented pharmacy-desert sub-area such as 9th Street/Italian Market, Grays Ferry, Eastwick, or Woodland Avenue · SVI-high tract with documented Rite Aid closure (4 of 5 documented PA-3 closures concentrated here)
IRA MFP Year 1 prices on 10 drugs reduce list price 38-79% (per MC-04). Federal price reduction operative at pricing layer. ASPE's analysis shows only 11% of non-LIS Part D enrollees in coinsurance plans spend less per prescription due to MFP — operational reach to constituent-level affordability is structurally narrower than headline list-price reduction suggests. Transportation pathway from prescription-write to fill-completion has structurally narrowed where nearest pharmacy has closed; SVI 30-40% closure correlation means closure pattern concentrates on compound-disadvantage tracts. The protection cannot reach the PA-3 constituent who cannot physically reach a pharmacy. The defining D4 SD3 paradox is the pricing-protection-vs-access-collapse simultaneity (G1-SD3-01 + G1-SD3-02; MC-04 + MC-07).
PA-3 OUD patient accessing buprenorphine via post-X-waiver pathway in pharmacy-desert sub-area
North/Northwest Philadelphia Core
PA-3 constituent OUD patient · post-MAT-Act prescribing eligibility expansion · documented pharmacy-desert sub-area · Aramingo Avenue corridor closure documented · ~3,000-4,000 PA-3 prescriber-eligible cadre · suspicious-order monitoring constraint operative under DEA Diversion Control architecture
MAT Act 2022 eliminated DATA 2000 X-waiver requirement; prescription written; pharmacy fill subject to suspicious-order monitoring; methadone-vs-buprenorphine racial-pattern asymmetry documented in academic literature. Pharmacy desert post-Rite-Aid intersects directly: federal X-waiver elimination expanded prescribing capacity at prescriber layer, simultaneous with PA pharmacy infrastructure attrition narrowing fill-completion layer. The MAT Act expanded the prescribing pathway at the moment PA pharmacy infrastructure attrition narrowed the fill pathway (G1-SD3-06; cross-ref SD6 G1-SD6-04).
PA-3 chronic-condition patient requiring biologic via specialty pharmacy
West Philadelphia Core
PA-3 constituent chronic-condition patient (rheumatologic, oncologic, or other biologic-requiring condition) · affiliated with small clinical practice not directly tied to major health system · requiring biologic via specialty pharmacy routing · biologic dispensing volume concentrates at health-system-affiliated specialty pharmacies (Penn / CHOP / Jefferson / Temple)
Specialty-pharmacy routing through Penn / CHOP / Jefferson / Temple specialty-pharmacy infrastructure; independents functionally excluded from specialty-pharmacy biologic-dispensing pathway; small clinical practices vs. major health systems carry differential specialty-pharmacy referral pathway access. The federal regulatory architecture treats specialty pharmacy access as a market mechanism; documented concentration at major-health-system specialty pharmacies produces structurally divergent access for small-clinical-practice-affiliated patients (G1-SD3-08; XC-11 application).
Black PA-3 SCD patient seeking gene therapy at Penn / CHOP ATC — the Philadelphia paradox
West Philadelphia Core
PA-3 constituent Black SCD patient · North/Northwest Philadelphia Core, Cobbs Creek-area West Philadelphia Core, or South Philadelphia Black sub-area · Penn or CHOP cell/gene therapy ATC at University City geographically present · Casgevy $2.2M / Lyfgenia $3.1M list · 15-year monitoring requirement post-administration
Cell/gene therapy capacity geographically concentrated in PA-3 (Penn / CHOP at University City) operates in proximity to predominantly Black PA-3 sub-areas with documented elevated SCD prevalence (SCD ~90% Black; ~100,000 Americans); yet uptake remains low. MC-05 substantially confirms low-uptake framing: Casgevy globally infused 64 patients in 2025 (30 in Q4 alone); ~165 cumulative first cell collections; ~300 referred to ATCs; ~90% reimbursed access per Vertex; provider education cited as significant barrier ("doctors are discouraging patients"); ~164 cumulative US uptake through 2025. Structural barriers: cost + ATC capacity + 15-year monitoring + clinical trial diversity gap legacy. Both/And: substantive cell-and-gene-therapy availability AND Philadelphia paradox low uptake (G1-SD4-01 = G1-XC-05; MC-05).
PA-3 child under school immunization requirement during vaccine policy litigation period
North/Northwest Philadelphia Core
PA-3 constituent child of school age · PADoH school immunization requirement · federal vaccine policy litigation period (June 2025 ACIP overhaul → March 16, 2026 federal court block → April 9, 2026 HHS charter rewrite per MC-02) · ~280,000 PA-3 children of school age · VFC program federal-state-local flow operative
June 2025 RFK Jr. removal of all 17 ACIP members; October/November 2025 vaccine removals; January 5, 2026 schedule overhaul (17 → 11 diseases). March 16, 2026 federal court block (Judge Brian E. Murphy, D. Mass.) — plaintiffs AAP, IDSA, APHA, ACP, Society for Maternal-Fetal Medicine, Massachusetts pediatric chapters, three Jane Doe individuals — found ACIP appointments violated FACA; halted 13 new appointments + all post-June 2025 votes + government memo enacting new schedule (per MC-02). April 9, 2026 HHS charter rewrite broadening ACIP scope to include "novel vaccine platforms such as mRNA vaccines." Pharmacy desert post-Rite-Aid reduces vaccine administration vector. Federal-state operational coherence stress during litigation period; PA / Philadelphia school exemption vs. requirement coherence flagged (G1-SD4-02; F4-T2P2-SD4-2).
PA-3 patient encountering algorithmic clinical decision-support tool post-LDT vacatur
West Philadelphia Core
PA-3 constituent patient · Penn / CHOP / Jefferson / Temple academic medical center · algorithmic clinical decision-support tool deployed · post-March 31, 2025 LDT vacatur · clinical algorithm deployment under CLIA-only oversight without federal premarket validation
Documented racial-pattern bias instances in clinical algorithms persist in broader literature without federal remediation pathway. CDRH capacity erosion per MC-07 (~260 fired including 40 from Digital Health Center of Excellence; Office of Women's Health "rendered effectively non-functional") compounds the operational gap precisely where the algorithmic decision-support remediation infrastructure would be developed. XC-11 application — small clinical practices may rely on LDTs for which post-vacatur replacement pathways are less developed; clinical decision-support tool deployment census may concentrate at academic-medical-center deployment with thinner small-practice deployment (G1-SD4-03; G1-SD4-04).
Black PA-3 menthol smoker in North Philadelphia compound-disadvantage sub-area
North/Northwest Philadelphia Core
PA-3 constituent Black menthol smoker · North/Northwest Philadelphia Core (highest documented marketing-density concentration) · documented elevated menthol smoking prevalence concentration · within SNAP-authorized retailer interior advertising 3.43x pattern geography · menthol = 35% of US cigarette sales / ~85% of Black smokers use menthol
The federal regulatory architecture acknowledged the disparate-impact pattern in its own regulatory preamble, developed the substantive remediation tool (menthol cigarette ban proposed rulemaking), withdrew the tool on January 21, 2025 (Trump's second day; RIN 0910-AI60; per MC-06), and decimated regulatory-development capacity through April 2025 CTP Office of Regulations RIF described per AP as "the entire office responsible for drafting new tobacco regulations" (per MC-07; CTP Director Brian King removed April 1, 2025; Bret Koplow Acting Director; CTP RIF subject to Rhode Island injunction). The disparate-impact remediation pathway through CTP's regulatory channels is structurally foreclosed (G1-SD5-01 = G1-XC-08; MC-06 + MC-07). AATCLC v. HHS in N.D. Cal. is the pending judicial pathway.
PA-3 underage resident seeking tobacco or vaping products in South Philadelphia
South/Southwest Philadelphia
PA-3 constituent under-21 individual · seeking tobacco or vaping product purchase · PA Act 14 of 2020 Tobacco 21 effective July 1, 2020 · Title 6 §6-700 retailer compliance architecture · PDPH retail enforcement · federal CTP user-fee-funded enforcement partnership
Federal Tobacco 21 (FFDCA Chapter IX as amended 2019) + PA Act 14 + Title 6 §6-700 + Title 10 §10-700 + PDPH enforcement. Documented retailer compliance variation by sub-area; cessation-pharmacotherapy access vector reduction post-pharmacy-desert (cross-ref SD3); under-21 vaping pathway access concentrates at retailer non-compliance points. The architecture's age-floor enforcement is operative; the upstream marketing-density and cessation-pharmacotherapy access architecture is where the structural gaps concentrate (G1-SD5-05; cross-ref SD3).
Small PA-3 tobacco retailer under Title 6 §6-700 density cap + 500-foot school buffer
West Philadelphia Core
PA-3 constituent small / independent tobacco retailer · PDPH Title 6 §6-700 density cap (1-per-1,000 retailer-population ratio) + 500-foot school buffer + license fee architecture · concentrated in compound-disadvantage sub-areas where SNAP-authorized retailer interior advertising 3.43x pattern operates · PDPH retail tobacco license
PDPH retail tobacco license application; density-cap compliance check; 500-foot school buffer compliance; license fee; ongoing compliance under Title 6 §6-700 + Title 10 §10-700; federal CTP retail compliance enforcement coordination. Small / independent tobacco retailers carry differential compliance burden against corporate-chain retailers whose compliance infrastructure absorbs regulatory burden differently. The marketing-density disparate-impact concentration is produced upstream at the corporate marketing decision layer (which retailer to advertise in; which advertising material to place; which products to promote); the enforcement architecture does not reach that upstream layer (G1-SD5-03 + G1-SD5-08; XC-11 application).
PA-3 OUD patient accessing buprenorphine post-X-waiver in pharmacy-desert sub-area
South/Southwest Philadelphia
PA-3 constituent OUD patient · post-MAT-Act prescribing eligibility expansion · documented pharmacy-desert sub-area · ~3,000-4,000 PA-3 prescriber-eligible cadre · DEA Diversion Control suspicious-order monitoring · cessation pharmacotherapy access vector reduction cross-cut SD3 + SD5
MAT Act 2022 eliminated DATA 2000 X-waiver requirement; prescription written; pharmacy fill subject to suspicious-order monitoring constraint; methadone-vs-buprenorphine racial-pattern asymmetry documented. Pharmacy desert post-Rite-Aid (cross-ref SD3) reduces buprenorphine pharmacy availability vector at sub-area level. XC-11 application — smaller treatment programs may have less capacity to absorb SAMHSA federal funding pressure than DBHIDS or larger institutional programs. The buprenorphine pharmacy availability gap operates at the federal-state-local intersection where the MAT Act expanded prescribing capacity at the same moment PA pharmacy infrastructure attrition narrowed the fill pathway (G1-SD6-01 + G1-SD6-04; cross-ref SD3).
PA-3 resident at the Kensington compound-incidence locus boundary intersection
North/Northwest Philadelphia Core
PA-3 constituent · northern boundary portion of North/Northwest Philadelphia Core · Kensington compound-incidence locus partially intersects PA-3 · documented structurally entrenched compound factors · Prevention Point demographics 62% white / 26% Black / 83% unhoused at the locus · medetomidine 83% Philadelphia drug supply by March 2025 · BTMPS 25% · xylazine continued co-occurrence
Parallel-infrastructure (harm-reduction + emergency response + outreach) engagement at locus; Prevention Point demographics document organizational engagement pattern at the locus itself, not the broader Black PA-3 OUD population engagement pattern (G1-SD6-02 careful framing preserved; gap-finding without pathologizing). Black PA-3 OUD patients engage treatment pathways through varied infrastructure: traditional treatment programs, peer-support programs, faith-based programs, family / community networks, and other pathways (F4-T2P2-SD6-1 retrieval target). Both-true framing critical: overdose mortality decline ~24% from 2022 peak + Mayor Parker $100M+ wellness ecosystem expansion + structurally entrenched compound factors all operate simultaneously (G1-SD6-05; G1-SD6-02).
PA-3 medical marijuana patient under today-effective Schedule III architecture
Northwest Philadelphia
PA-3 constituent medical marijuana patient · qualifying-condition certification under PA Act 16 of 2016 · dispensary access at PA-3-located dispensary · DEA Marijuana Schedule III Final Order effective April 28, 2026 (FR Doc. 2026-08176) · Trump EO 14370 (December 18, 2025) · DEA Medical Marijuana Dispensary Registration Portal opens April 29, 2026 at 9:00 AM EST · $794 annual application fee · 60-day priority window through ~June 27, 2026
Section 280E deduction disallowance lifted effective immediately for state-licensed medical cannabis; Treasury/IRS guidance forthcoming on transitional rules; DOJ Final Order encouraged Treasury to consider retrospective relief for prior tax years. New DEA hearing on broader rescheduling June 29 - July 15, 2026 is next inflection point. Adult-use cannabis remains Schedule I; synthetically derived THC (delta-10) excluded; only FDA-approved products + state-licensed medical cannabis rescheduled. XC-11 application — smaller dispensary operators (independent vs. multi-state) under PA Act 16 architecture carry differential capacity to navigate dual federal-state regulatory pathway during 60-day priority window (G1-SD6-06; MC-01).
PA-3 constituent navigating the federal-cluster simultaneity at Mellon Independence Center
North/Northwest Philadelphia Core
PA-3 constituent simultaneously affected by multiple SDs · federal-cluster anchor at FDA Philadelphia District + FSIS Philadelphia District 60 + CMS Region III + DEA Philadelphia Field Division · Mellon Independence Center, 900 US Customhouse, 2nd & Chestnut, Philadelphia 19106 · federal-cluster as geographic-coincidence point
SD1 + SD2 + SD3 + SD4 + SD5 federal layers concentrate at FDA Philadelphia District at Mellon Independence Center. FSIS Philadelphia District 60 operates at same address. CMS Region III administers Medicare Part D + IRA MFP. DEA Philadelphia Field Division administers controlled substances. 5 of 6 D4 sub-domains at HIGH or EXTREME federal-agency administrative vulnerability composite as of execution; SD6 alone at MODERATE. The composite is qualitatively unique in scope and concentration (G1-SD7-01 + G1-SD7-02; MC-07 April 2025 FDA RIF ~3,500 = 19% workforce; CDER ~1,000 lost; CDRH ~260 fired; CTP Office of Regulations decimated).
PA-3 constituent at the anchor-institution pathway (Penn / CHOP / Jefferson / Temple)
West Philadelphia Core
PA-3 constituent · navigating Penn / CHOP / Jefferson / Temple academic-medical-center infrastructure · SD3 specialty pharmacy + SD4 cell/gene therapy + SD6 addiction-treatment-coordination interfaces · Penn $100M+ pledge supporting SDP environmental management (cross-cut D13 SD5 + D6 SD4 + D9 SD4)
Anchor-institution concentration produces the Philadelphia paradox at SD4 (cell/gene therapy ATC concentration adjacent to populations most affected by SCD; G1-XC-05 = G1-SD4-01) and the specialty pharmacy access asymmetry at SD3 (G1-SD3-08). D4 intersects at the substantive-program-availability dimension (Casgevy + Lyfgenia) without architecturally extending the five-dimensional anchor accountability framework completed at D6. Both/And designation preserved at SD4: substantive cell-and-gene-therapy availability AND Philadelphia paradox low uptake (~164 cumulative US uptake through 2025 per MC-05) (G1-SD7-06).
PA-3 constituent at compound-disadvantage geography simultaneous concentration
South/Southwest Philadelphia
PA-3 constituent in North/Northwest Philadelphia Core or portions of West Philadelphia Core or South Philadelphia · simultaneous concentration of SD1 + SD2 + SD3 + SD4 + SD5 + SD6 documented patterns at sub-area level · the Compound Disadvantage Geography Matrix as central D4 finding-presentation infrastructure
SD1 highest FI + SD2 cheaper-cut concentration + SD3 pharmacy desert (4 of 5 documented PA-3 Rite Aid closures in South/Southwest) + SD4 elevated SCD prevalence + SD5 highest marketing density 3.43x + SD6 OUD prevalence or Kensington locus boundary intersection. The pathway is the constituent-level cumulative effect of structural-pattern simultaneity at sub-area level. The matrix preserves sub-area-level cross-SD pattern visibility, which is the structural-architecture analytical layer where the synthesis becomes substantively legible (G1-SD7-06; central D4 finding-presentation infrastructure).